Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

FDA Approval of Remdesivir — A Step in the Right Direction

Open access
Rubin, Daniel, Chan-Tack, Kirk, Farley, John, Sherwat, Adam · 2020 · New England Journal of Medicine

Abstract

secretary of health and human services declared a public health emergency in response to Covid-19.This disease, caused by the SARS-CoV-2 virus, can have severe manifestations, including pneumonia, respiratory failure, multiorgan failure, and death.Although there is now an extensive global search for therapies, there remains an unmet need for safe and effective treatment options for patients.On May 1, 2020, on the basis of preliminary results from phase 3 trials, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to allow the use of remdesivir for the treatment of suspected or laboratory-confirmed Covid-19 in adult and pediatric patients hospitalized with severe disease. 1 The scope of the EUA was subsequently expanded on August 28, to allow use in a broader hospitalized population.On October 22, the FDA approved remdesivir for use in adults and pediatric patients (12 years of age or older and weighing at least 40 kg) for the treatment of Covid-19 requiring hospitalization. 2 This approval was based largely on the results of three phase 3 clinical trials in hospitalized patients with disease of varying severity.These were the Adaptive

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmp2032369

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 212

Metadata

Authors
Rubin, D., Chan-Tack, K., Farley, J., & Sherwat, A.
Venue
New England Journal of Medicine
Published
2020-12-31
Volume
383
Issue
27
Pages
2598-2600
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3106878713
Cited by
212
References
2
FWCI
5.37
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval of Remdesivir — A Step in the Right Direction. https://app.cochat.ai/papers/10.1056/nejmp2032369
The paper
Rubin, D., Chan-Tack, K., Farley, J., & Sherwat, A. (2020). FDA Approval of Remdesivir — A Step in the Right Direction. New England Journal of Medicine. https://doi.org/10.1056/nejmp2032369

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.